Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial [Image: see text] [Image: see text]

OBJECTIVE: B cells and the humoral immune system have been implicated in the pathogenesis of multiple sclerosis (MS). This study sought to evaluate the efficacy, safety, and tolerability of add-on therapy with rituximab, a monoclonal antibody that depletes circulating B cells, in subjects with relap...

Full description

Saved in:
Bibliographic Details
Main Authors: Naismith, R.T., Piccio, L., Lyons, J.A., Lauber, J., Tutlam, N.T., Parks, B.J., Trinkaus, K., Song, S.K., Cross, A.H.
Format: Artigo
Language:Inglês
Published: American Academy of Neurology 2010
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2882224/
https://ncbi.nlm.nih.gov/pubmed/20530322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181e24373
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items